KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of mineral and bone disorders in chronic kidney disease

Polskie Archiwum Medycyny Wewnetrznej

Volumn 120, Issue 7-8, 2010, Pages 300-306

  Matuszkiewicz Rowińska, Joanna ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Chronic kidney disease; KDIGO; Mineral and bone disorders; Renal osteodystrophy; Vascular calcifications

Indexed keywords

BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; HUMAN GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D DERIVATIVE;

ABDOMINAL RADIOGRAPHY; BONE BIOPSY; BONE DENSITOMETRY; CALCIUM BLOOD LEVEL; CHILDHOOD DISEASE; CHRONIC KIDNEY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIALYSIS; DIET THERAPY; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; ECHOCARDIOGRAPHY; FRAGILITY FRACTURE; GRAFT RECIPIENT; HEART ARRHYTHMIA; HUMAN; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; JAW OSTEONECROSIS; NEPHRITIS; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; RENAL OSTEODYSTROPHY; REVIEW; SOFT TISSUE CALCIFICATION; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 77955879945     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.953     Document Type: Review

References (11)

1. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009; 76 (Suppl 113): S3-S130.
2. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 284-286.
3. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42 (Suppl 3): S1-S201.
4. Spasovski GB, Bervoets AR, Behets GJ, et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant. 2003; 18: 1159-1166.
5. Klawansky S, Komaroff E, Cavanaugh PF Jr, et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporosis Int. 2003; 14: 570-576. (Pubitemid 36975556)
6. Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000; 58: 396-399.
7. Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the Fracture Intervention Trial. J Bone Miner Res. 2007; 22: 503-508.
8. Miller PD, Roux C, Boonen S, et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gauft method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005; 20: 2105-2115. (Pubitemid 41698774)
9. Sprague SM, Belozeroff V, Danese MD, et al. Abnormal bone and mineral metabolism in kidney transplant patients - a review. Am J Nephrol. 2008; 28: 246-253.
10. Julian BA, Laskow DA, Dubovsky J, et al. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991; 325: 544-550.
11. Weisinger JR, Carlini RG, Rojas E, et al. Bone disease after renal transplantation. Clin J Am Soc Nephrol. 2006; 1: 1300-1313.